ArticleJournal of inflammation research2025
Characterization of Cuproptosis-Related LncRNAs Prognostic Signature and Identification of LINC02285 as a Novel Biomarker for Ovarian Cancer.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cuproptosis, a novel form of cell death triggered by copper ion accumulation, has shown potential in cancer therapy, particularly through the involvement of cuproptosis-related lnRNAs (CRLs). In-depth analyses exploring the relationship between CRLs and ovarian cancer (OC) are currently limited. Methods: LASSO-Cox regression analysis was conducted to assess the prognostic significance of CRLs and develop a cuproptosis-related prognostic model. Furthermore, tumor immune microenvironment and drug sensitivity were analyzed using ssGSEA, GSVA, ESTIMATE, and CIBERSORT algorithms. Finally, the tumorigenic effect of LINC02285 in OC and its correlation with cuproptosis were investigated by in vitro cell experiments. Results: We identified 138 CRLs correlated with cuproptosis-related genes (CRGs), 4 key CRLs (AC080038.1, AC083880.1, LINC00861, and LINC02285) were used to develop a prognostic model that effectively distinguished between low-risk and high-risk patients with significant differences in overall survival and progression-free survival. ROC curve analysis further validated the predictive capacity of the signature. Additionally, the low-risk group had a favorable prognosis associated with a protective immune microenvironment and a better response to targeted drugs. Conversely, the high-risk group displayed aggressive tumor features and poor immunotherapy outcomes. Validation through qPCR confirmed the differential expression of these CRLs in OC cells compared to normal ovarian cells, underscoring their potential significance in tumor biology. Bioinformatics analyses corroborated the association of LINC02285 with poor prognosis in OC patients. Functional experiment results showed that abnormal expression of LINC02285 could significantly regulate the proliferation and migration of OC cells. In addition, overexpression of LINC02285 markedly attenuated the inhibitory effects of Elesclomol-CuCl Conclusion: Our study established a prognostic model based on 4 CRLs to assess overall survival and the immune microenvironment in OC patients. As a high-risk factor, LINC02285 demonstrates potential as a prognostic biomarker for OC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.